Common Contracts
1 similar Shared Care Agreement contracts
ContractShared Care Agreement • November 9th, 2022
Shared Care Agreement for Degarelix (Firmagon®) for the treatment of adult male patients with advanced hormone-dependent ProstateCancer 1. Background Degarelix is a selective gonadotrophin releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that removes the source of androgen. Unlike GnRH agonists, GnRH antagonists do not induce a LH surge with subsequent testosterone surge/ tumour stimulation and potential symptomatic flare after the initiation of treatment.Patients do not require a course of anti-androgens as no tumour flare is caused by degarelix. 2. Indications (Please state whether licensed or unlicensed) Degarelix is indicated in metastatic prostate canc
